Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07197905Phase 2Recruiting

Restoring Iron Deficiency in POTS

Role: collaborator

NCT03218761Active Not Recruiting

POTS NET mRNA Functional Correlation With NET Activity

Role: collaborator

NCT03919773Phase 1Completed

IVIG (Gamunex-C) Treatment Study for POTS Subjects

Role: collaborator

NCT05409651Not ApplicableActive Not Recruiting

Phenotyping Mitochondrial and Immune Dysfunction in POTS With Targeted Clinical Intervention.

Role: collaborator

NCT04186286Phase 2Recruiting

Crossover Study of Propranolol vs Ivabradine in POTS

Role: collaborator

NCT03930914Not ApplicableCompleted

Vagus Nerve Stimulation in Treatment of Postural Orthostatic Tachycardia Syndrome

Role: collaborator

NCT03602482Not ApplicableCompleted

Standing Cognition and Co-morbidities of POTS Evaluation

Role: collaborator

All 7 trials loaded